GLP-1
Orforglipron
Own facility · GLP-1 Peptides
Investigational. This is an investigational compound and is not approved for marketing. Material and development services are offered only to qualified entities for research and pharmaceutical development, subject to applicable law.
Orforglipron is an investigational oral small-molecule GLP-1 receptor agonist under clinical development for type 2 diabetes and obesity. BOOKPHARM supports orforglipron through CDMO development of the active ingredient and intermediates.
Supply offerings
| Business line | Business model | Regulatory status |
|---|---|---|
| FDFGLP-1 | API + FDF CMO/Supply | CDMO |
| APIGLP-1 | CDMO/CMO of API+intermediates | NDC |
Supplied for pharmaceutical manufacturing and R&D by licensed and qualified entities. Not for human use as supplied. Availability is subject to regulatory approval in the buyer's jurisdiction.